Premium
Biweekly COP‐BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony‐stimulating factor (G‐CSF) for intermediate‐grade non‐Hodgkin's lymphoma
Author(s) -
Niitsu Nozomi,
Umeda Masanori
Publication year - 1996
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1996.tb01336.x
Subject(s) - procarbazine , medicine , vincristine , prednisone , regimen , cyclophosphamide , non hodgkin's lymphoma , bleomycin , adverse effect , granulocyte colony stimulating factor , chemotherapy , combination chemotherapy , surgery , oncology , gastroenterology
We evaluated the efficacy and adverse effects of biweekly COP‐BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) therapy combined with granulocyte colony‐stimulating factor (G‐CSF) for treating non‐Hodgkin's lymphoma (NHL). A complete remission was achieved in 65 (90.3%) of the 72 patients. The median follow‐up period was 28 months, and 64 patients were alive at the time of writing. Treatment was delivered as scheduled to 61 patients. G‐CSF made it possible to shorten the interval between courses of chemotherapy. One of the 72 patients died of granulocytopenia and pneumonia; no other severe infections were noted. Further studies regarding adverse effects on organs other than the bone marrow are required to improve the long‐term results of combination therapy on NHL.